Diabetes management has changed significantly with the development of Continuous Glucose Monitoring (CGM) technology. What once required multiple finger-stick tests throughout the day can now be supplemented or depending on the individual’s treatment plan can sometimes be replaced by CGM. It can provide people with diabetes and their healthcare providers with something that traditional finger-stick testing cannot- a view of glucose levels and trends throughout the day and night. That raises an important question – Do patients have to wait until their diabetes progresses to a more advanced stage of requiring Insulin therapy before insurance will cover this technology? House bill HB648 with the proposed amendment seeks to address that question by expanding insurance coverage for CGM when prescribed by a physician for patients at earlier stages of diabetes.

What is a CGM?
A continuous glucose monitor uses a small sensor placed just beneath the skin to measure glucose levels. The information is transmitted to a smartphone app or compatible receiver, allowing the user to see glucose readings and trends in real time. Many CGM sensors can be worn for approximately 14 days. This can significantly reduce the need for repeated finger-stick testing and provide information throughout the day and night.
Traditional blood glucose testing provides a snapshot of the glucose reading at a particular moment. CGM, by contrast, can show whether glucose is rising, falling or remaining relatively stable. That difference can be particularly useful because glucose levels can change for many reasons, including food, physical activity, medication, stress and other factors.

Why Real-Time Information Matters
Diabetes is a chronic condition that requires ongoing management. Persistently high blood glucose can contribute to complications involving the heart, kidneys, eyes, nerves, blood vessels and feet. Very low or rapidly changing glucose levels can also present immediate concerns. CGM technology can provide alerts when glucose levels move above or below predetermined thresholds. Instead of waiting for symptoms to appear, a patient may receive an alert that their glucose level is entering a concerning range. Symptoms of abnormal glucose levels can include dizziness, fatigue, headache, blurred vision and other changes. With traditional testing, a person may need to recognize symptoms, perform a finger-stick test and then determine what action to take. CGM can provide another layer of information by continuously monitoring glucose and alerting the user to significant changes. This doesn’t mean CGM eliminates the need for medical advice or other forms of diabetes management. Rather, it gives patients and healthcare providers additional information that can be used as part of an overall treatment plan.

The Question of Insurance Coverage
One of the biggest barriers to wider CGM use is insurance coverage. Under many current insurance policies, CGM coverage is tied to specific treatment requirements, including insulin therapy. As a result, many people do not qualify for insurance-covered CGM until their diabetes has progressed to a stage requiring more intensive treatment. This creates an important policy question – Should access to a diabetes-monitoring technology depend primarily on the stage of the disease, or should it depend on whether a physician determines that the technology is medically appropriate for the individual patient? The proposed amendment to HB648 takes the latter approach. Under the proposed change, a physician’s prescription would be required for CGM coverage, allowing the treating healthcare professional to determine whether CGM is appropriate for a patient.

Could Earlier Monitoring Help Prevent Bigger Problems?
The objective of earlier CGM access is not simply to provide patients with another piece of technology. The broader goal is to support better diabetes management before complications become more difficult and expensive to treat.

CGM can help patients understand how their glucose responds to meals, physical activity, medications and other factors. Over time, this information can reveal patterns that may not be apparent from occasional finger-stick readings. That information can also be useful to healthcare providers when evaluating a patient’s diabetes management and making treatment decisions. For some patients, earlier access to this information could potentially help them make changes before their diabetes progresses and requires more intensive treatment.

A Potential Cost-Saving Opportunity
There is also a financial argument for considering earlier CGM coverage. A CGM device can cost approximately $100 per month or less, depending on the device. Compared with the potential costs associated with advanced diabetes treatment, hospitalization and complications, supporters argue that covering CGM earlier could represent a relatively modest investment. If better monitoring and earlier intervention help reduce serious diabetes related complications for some patients, insurers could potentially save money over the long term. In other words, the question isn’t only about the cost of providing CGM coverage today. It is also about whether a relatively small investment in monitoring could help avoid significantly greater healthcare costs later. Of course, the actual impact on healthcare spending will depend on individual patients, treatment plans, insurance policies and clinical outcomes. More broadly, however, the concept is straightforward – early management should be preferable than to wait until a health problem becomes more complicated and expensive to treat.

Giving Physicians a Greater Role
At the heart of the proposed HB648 amendment is the role of the physician. Every person with diabetes is different. Their glucose patterns, medications, lifestyle, risks and treatment needs can vary considerably. A physician who understands a patient’s individual circumstances is in a position to determine whether CGM is an appropriate tool.

Requiring a prescription maintains a medical decision-making process while potentially allowing patients to access CGM earlier than they otherwise could under restrictive coverage policies. For patients, this could mean earlier access to continuous information. For physicians, it could provide additional data to support treatment decisions. And for insurers, it could potentially represent an opportunity to invest in earlier management rather than paying substantially more when complications develop.

Looking Ahead
CGM technology has changed the way many people approach diabetes management by making continuous glucose information available throughout the day and night. The discussion around HB648 is ultimately about when patients should be able to access that technology. Should a patient have to wait until diabetes becomes more advanced and insulin therapy is required, or should a physician be able to prescribe CGM when it is medically appropriate at an earlier stage? Expanding insurance coverage for physician-prescribed CGM could give patients another tool to understand and manage their diabetes proactively. For many people living with diabetes, the earlier they have useful information, the more opportunities they may have to act on it for better diabetes management.